Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Dec 11, 2023

Oracle’s “Business Is Good and Getting Better”
Image Source: Peter Kaminski. On December 11, Oracle reported mixed second-quarter results for its fiscal 2024 that showed total revenue advancing 5% on a year-over-year basis (4% in constant currency), slightly lower than expectations, and non-GAAP earnings per share of $1.34 that came in slightly ahead of what the market was looking for. The company’s non-GAAP operating margin of 43% in the quarter helped to drive non-GAAP net income 14% higher than the same period a year ago (11% in constant currency). We’re not letting the slight miss on the top line sway us from our constructive stance on shares. Our fair value estimate stands at $108 per share, about in-line with where shares are currently trading.

Dec 7, 2023

Latest Report Updates
Check out the latest report refreshes on the website.

Nov 29, 2023

Latest Report Updates
Check out the latest report refreshes on the website.

Nov 27, 2023

How Do We Use the Valuentum Buying Index?
Image: We highlighted Exxon Mobil to start 2022, and the stock was one of the best performers in the S&P 500 last year. Exxon Mobil became a “Valuentum” stock last year, with shares being undervalued, exhibiting a strong technical breakout, and sporting an attractive dividend yield to boot. The stock became a huge winner. Note: Exxon is no longer included in the simulated newsletter portfolios. The image is an excerpt from an email sent to members January 5, 2022.We answer one of the most frequently asked questions about the Valuentum Buying Index.

Nov 8, 2023

Gilead's Oncology Business Could Represent One Third of Product Revenue By 2030
Image: Gilead’s potential in oncology speaks to long-term sustainability. On November 7, Gilead Sciences reported better-than-expected third-quarter results with revenue and non-GAAP earnings per share handily beating the consensus estimates. Gilead was once a market darling having cured hepatitis C, but success in this area has forced the company to reinvent itself, and it continues to make solid progress in HIV product sales and oncology (Trodelvy and Cell Therapy). We have Gilead on our radar for consideration, and the company’s dividend yield of ~3.7% pays investors to wait for its promising pipeline to flourish. We value Gilead north of $100 per share, far above where it is currently trading.

Oct 31, 2023

3 Mid Caps With Net Cash And Strong Free Cash Flow
Image: Chewy's best-in-class customer service is paying off in strong free cash flow generation. We're huge fans of companies with net cash on their balance sheet and strong free cash flow generating potential. This view has led us to favor the areas of big cap tech and the stylistic area of large cap growth in the newsletter portfolios, but there are other companies emerging with similar economics on a smaller scale. Chewy, Inc. E.L.F Beauty and DocuSign are three that come to mind, and all three of these names boast a strong balance sheet and favorable free cash flow dynamics. Each of these companies is also benefiting from secular growth trends as they seek to gain market share against rivals. Though certainly not without valuation risk as the trajectory of free cash flow expectations will certainly cause volatility in their respective stocks, we think all three may be worthy of consideration for the aggressive, risk-seeking investor targeting long-term capital appreciation.

Oct 30, 2023

3 Net-Cash-Rich, Free-Cash-Flow Generating, Secular Growth Powerhouses
Image: Shares of Microsoft, Alphabet, and Meta Platforms have trounced the market return so far in 2023. We think a holistic view to a company's fundamentals provides an upper hand when it comes to outperforming the market, but we also feel that the discounted cash-flow model is an indispensable tool to help investors collect all of their thoughts and quantitatively put them together within valuation to arrive at what a company is worth. After all, the stock market is an expectations game, where expectations of free cash flow form the baseline for value, and changes in them heavily influence the direction of share prices. We like stocks that have strong net cash positions on the books and have a high probability of achieving better-than-expected free-cash-flow generation in coming years. In this article, we'll talk about the cash-based sources of intrinsic value at three large cap growth names.

Oct 25, 2023

Alphabet and Meta Are Net-Cash-Rich, Free-Cash-Flow Generating, Secular-Growth Powerhouses
Image: Free cash flow growth at Alphabet has been phenomenal during the first nine months of 2023. Both Alphabet and Meta are net-cash-rich, free-cash-flow generating, secular-growth powerhouses. Though cloud revenue growth and the pace of expense expansion at Alphabet are concerns, and while Meta may experience some softness in advertising revenue during the current quarter, both entities’ quarterly performances during the calendar third quarter showcased why they have been market darlings during 2023. Note: We’ve corrected our updated report on Alphabet. We had previously uploaded an incorrect version, but this version (pdf) has now been corrected. There is no change to the updated fair value estimate of $133 per share.

Oct 22, 2023

There Will Be Volatility
Image: An ETF tracking Russell 1000 "growth" stocks has outperformed an ETF tracking Russell 2000 "value" stocks since the beginning of 2021. To us, the market remains hypersensitive to almost every economic data point that hits the wires, and we’re just not going to play that game. The macro headlines and never-ending news flow are what many quant and algorithmic traders are trading on, and to a very large extent, for investors with a long-term horizon, these macro data points just don’t factor into the equation. When valuing equities, we’re always after mid-cycle expectations, not peak or trough performance, so our valuations implicitly embed a "normal" recession. Warren Buffett didn’t become a billionaire buying and selling on macro data points, and volatility is simply to be expected given the proliferation of price-agnostic trading these days. Instead of panicking over higher interest rates, we think investors should view the Fed’s work thus far as future potential dry powder to stimulate both the economy and the markets. Whenever you feel like stocks are no good, have a read of Warren Buffett’s classic piece written during the Great Financial Crisis, “Buy American. I Am.” To us, we still like stocks for the long run. Happy investing!

Sep 20, 2023

Fed Rate Decision, UAW Strike Continues, Microsoft Ups Payout
Image Source: Mike Mozart. If you’re thinking like us about the ongoing Fed rate-hiking cycle, you’re probably thinking that perhaps we’ll see another rate hike or two down the road, even if the Fed pauses at today’s September 20 meeting. However, whether the Fed pauses from here on out or executes a couple more hikes, it really shouldn’t matter much to long-term investors. From where we stand, the conversation about interest rates should now be shifting away from worries about elevated inflation to the future positive prospects that correspond to the work that the Fed has already done. With the market-cap weighted S&P 500 just a stone’s throw away from all-time highs, despite aggressive contractionary monetary policy, we believe the market may start to view the existing levels of “high” near-term interest rates as dry powder for the Fed to stimulate the economy in the future, if or when it’s needed. The Fed has now built up a very nice insurance policy with little damage done to the U.S. stock market, and we think equities, particularly the stylistic area of large cap growth, may continue to reward investors as such a positive view is eventually factored in. New highs may once again be in the cards, and we remain bullish on the equity markets today, despite the ominous volatility experienced the past 20+ months.